A comprehensive view of American Society of Hematology (ASH). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bristol Myers Squibb presents two early studies evaluating potential first-in-class oral CELMoD agent Golcadomide for the treatment of non-hodgkin lymphomas at ASH 2023

Bristol Myers Squibb announces updated results from three key multiple myeloma research programs at ASH 2023; the programs include CAR T BMS-986393, CELMoD agent mezigdomide and the T cell engager alnuctamab

Pfizer’s experimental injectable drug, marstacimab, shows positive results in reducing bleeding episodes for hemophilia A and B patients; Phase 3 results presented at the annual meeting for the American Society of Hematology

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

Bristol Myers Squibb presents new data at ASH 2023 demonstrating clinical benefit across B-cell malignancies with Breyanzi as a second-line treatment in high-risk follicular lymphoma and in relapsed or refractory chronic lymphocytic leukemia

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count